Replies to post #457905 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Anavex 3-71 in New Schizophrenia Trials

Of course, blarcamesine against Alzheimer's is the major target for Anavex. But be aware of the company's new trials of Anavex 3-71 to safely and effectively treat patients with schizophrenia:

ANAVEX3-71-SZ-001 is a two-part study. The first part is Part A: Multiple Ascending Dose, PK, safety, and dose selection. The second part is Part B: Double Blind, Placebo Controlled for exploratory efficacy and continued repeat-dose safety. This study will investigate the effects of ANAVEX3-71 in patients with Schizophrenia for the first time. This is an in-patient study. In both parts, participants will undergo either 10 or 28 days of dosing (Part A and Part B, respectively). Standard clinical outcome measures used in the clinic and novel fluid and electrophysiological biomarkers will also be assessed.

https://classic.clinicaltrials.gov/ct2/show/NCT06245213

The market for a safe, effective schizophrenia drug is massive. There are good indications that Anavex 3-71 will be able to provide favorable treatment outcomes. We will all be watching for results from these trials.